B-Cell Non-Hodgkin Lymphoma Archives

Novartis’ Kymriah does not meet primary endpoint in late-stage study

Analysts, B-Cell Non-Hodgkin Lymphoma, Clinical Data, Clinical Trial Endpoints, Clinical Trials, Event-Free Survival (EFS), Novartis, Potential Blockbusters, Primary Endpoints, R&D, Therapeutics

Novartis said the company’s Kymriah CAR-T therapy did not meet the drug’s primary endpoint of event-free survival in a phase III study in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment.

CRISPR Pioneer Caribou Nets $115 Million to Advance Promising Pipeline

Business, CAR-T Therapy, Chimeric Antigen Receptor Natural Killer T Cells (CAR-NKT cells), Clinical Trials, CRISPR, Financing, Gene Editing, Immune Cells, Product Pipeline, R&D, Relapsed/refractory B cell non-Hodgkin lymphoma, Series C

Caribou Biosciences secured $115 million in an oversubscribed Series C financing round that will be used to advance the company’s pipeline of wholly owned allogeneic immune cell therapies for oncology and its next-generation CRISPR technology platform.

Bristol-Myers and Celgene's Liso-Cel Hits Mark in Multiple Cancer Studies

American Society of Hematology (ASH) Annual Meeting, B-Cell Non-Hodgkin Lymphoma, Cancer, CAR-T Therapy, Chronic Lymphocytic Leukemia (CLL), Clinical Trials, Hematopoietic Stem Cell Transplantation (HSCT), Immune Cells, R&D, Small Lymphocytic Lymphoma (SLL)

Bristol-Myers Squibb announced positive results for the CAR-T therapy lisocabtagene maraleucel (liso-cel) in three studies at the American Society of Hematology Annual Meeting.